Wed. 10 Apr 2024, 2:55am ET
Benzinga
News
- IPH45 is a novel and differentiated exatecan-Antibody Drug Conjugate targeting Nectin-4
- In PDX models of urothelial tumors, IPH45 has stronger activity than approved Nectin-4 targeting EV. IPH45 shows anti-tumor efficacy in various solid tumor and EV-refractory models
- Preclinical efficacy and toxicology data support further development of IPH45 which is progressing towards the clinic with IND planned in 2024